Literature

Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded

Retrieved on: 
Monday, April 22, 2024
Science (journal), Mortality, FDA, Pediatric Research, Protein, Chromatin, Cell, Limb–girdle muscular dystrophy, Research, American Philosophical Society, National Cancer Institute, Molecular biology, Life, Gene, Quran, Food, LGMD, SMA, RNA, DMD, Spinal muscular atrophy, Infant, Dystrophin, Nationwide, Duchenne muscular dystrophy, Ageing, National academy, Hospital, Cancer research, Literature, DNA, Therapy, Gene expression, Muscular dystrophy, Chromosome, USD, Stanford University, Cancer, Islamic studies, Muscle weakness, Disease, Vilcek Foundation, Patient, Assay, Society, Listeria monocytogenes non-coding RNA, Pharmaceutical industry

Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.

Key Points: 
  • Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.
  • Gene therapy offers a solution by addressing this genetic anomaly, allowing the body to produce dystrophin and halt muscle degeneration.
  • Ludwig Professor of Cancer Research at Stanford University, has been awarded King Faisal Prize for Science in Biology.
  • Since 1979, King Faisal Prize in its 5 different categories has awarded 295 laureates who have made distinguished contributions to different sciences and causes.

From plumbing drains to Dostoyevsky: Nicholas Hallers' transformative trek toward a Ph.D

Retrieved on: 
Wednesday, April 17, 2024
Education, Baylor University, COVID, Learning, NRG Stadium, St. Michael's Church, Classical tradition, English literature, Catholic Church, Literature, Frassati, Magnolia High School, Sam Houston State University, Rosary, SHSU, Lone Star College System

However, Hallers recalled, “My feelings about education had not changed and had, in fact, become very habituated and stable.

Key Points: 
  • However, Hallers recalled, “My feelings about education had not changed and had, in fact, become very habituated and stable.
  • First, for his father, a restauranteur who had wanted his son to study actuarial mathematics.
  • “Freddy Grimes of Sargent Plumbing and Michael Rodriguez of Mike’s Plumbing are to be credited with whipping me into shape as far as work ethic goes,” he said.
  • He leads me beside still waters; he restores my soul.’”
    Congratulations to Nicholas Hallers, UST Class of 2024.

Change in Leadership at AFB’s Journal of Visual Impairment & Blindness as Longtime Editor in Chief Sandra Lewis Steps Down, Robert Wall Emerson of Western Michigan University to Fill the Role

Retrieved on: 
Wednesday, April 17, 2024
ECC, Education, Research, Marilyn, Florida State University, Visual impairment, Life, Communication studies, Mathematics, Special education, Journal, Paratriathlon, Learning, Uncertainty, Literacy, Jimmy Buffett, Literature, FSU, Otorhinolaryngology, Dog, Orientation, San Francisco State University, Editorial, Deafblindness, Distinguished Service Award, Retirement, AER, Student, Division, Specialization, Acoustics, University, Textbook, Blind, Exceptional Children, Vanderbilt University, Rehabilitation, COMS, Curriculum, Management

Robert Wall Emerson, Ph.D., Western Michigan University, the journal’s research editor since 2012, will step into the role in July 2024.

Key Points: 
  • Robert Wall Emerson, Ph.D., Western Michigan University, the journal’s research editor since 2012, will step into the role in July 2024.
  • Despite her busy schedule, Dr. Lewis graciously accepted the role of editor-in-chief of JVIB in 2015.
  • In 2004, he moved to Western Michigan University, where he currently works as a professor in the Department of Blindness and Low Vision Studies.
  • Taken together with his vast areas of expertise, Dr. Wall Emerson is the natural choice to succeed Dr. Lewis as editor in chief of the journal.

Leading Radiation Oncologist Dr. Steven E. Finkelstein Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Tuesday, April 30, 2024
Medical Supplies, Biotechnology, Practice Management, Managed Care, Health, General Health, Radiology, Oncology, Medical Devices, Hospitals, Clinical Trials, Corporation, Micron Technology, University, Bangladesh Technical Education Board, Kidney, Hospital, Clinical research, Breast, National Cancer Institute, NMS, Literature, CARE, Prostate cancer, Radiation therapy, Patient, National Institutes of Health, Medicine, Physician, Lung, Radiation, Cancer, Medical imaging

Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals.

Key Points: 
  • Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals.
  • Radiation Oncology is the region’s leading provider of comprehensive cancer care services, providing the most advanced, effective treatments available for urological and other types of cancers.
  • Steven Finkelstein’s extensive experience in radiation oncology care and his leadership in the medical field will be a tremendous asset to U.S. Urology Partners, Associated Medical Professionals of NY and most importantly to individuals receiving cancer care in the Central New York region.
  • I am excited to join the team of Associated Medical Professionals of NY and look forward to helping patients in the community.”

Jackson Adds Protected Lifetime Income Benefit to RILA Suite

Retrieved on: 
Monday, April 29, 2024
Personal Finance, Finance, Consulting, Professional Services, Insurance, Ecosystem, Risk, Literature, Retirement, Jackson National Life, Marketing, JXN, Life insurance

Jackson National Life Insurance Company ® (Jackson®), the main operating subsidiary of Jackson Financial Inc.1 (NYSE: JXN), today launched +Income, an add-on benefit available for an additional charge, offering guaranteed2 lifetime income3 through Jackson’s Market Link Pro® suite of registered index-linked annuities (RILAs).

Key Points: 
  • Jackson National Life Insurance Company ® (Jackson®), the main operating subsidiary of Jackson Financial Inc.1 (NYSE: JXN), today launched +Income, an add-on benefit available for an additional charge, offering guaranteed2 lifetime income3 through Jackson’s Market Link Pro® suite of registered index-linked annuities (RILAs).
  • +Income enables clients to create an immediate income stream or defer withdrawals, providing the opportunity to grow income over time.
  • To coincide with the launch of +Income, the tool now includes a new option to illustrate how lifetime income can impact client portfolios.
  • "Jackson has a strong track record of serving as a trusted provider of guaranteed lifetime income strategies for financial professionals and their clients,” continued Sward.

Cognito Therapeutics Announces Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting

Retrieved on: 
Monday, April 29, 2024
Medical Devices, Health, Neurology, Research, Science, Biotechnology, Alzheimer's disease, Humanism, MCI, International Society, Literature, Patient, Caregiver, Cognito, Pharmacoeconomics, Therapy, Quality of life, Ageing, Pharmaceutical industry

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA.

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA.
  • The presented research is a targeted literature review of the clinical, humanistic, and economic burden of Alzheimer’s Disease (AD).
  • This surge underscores the pressing need for improved understanding and management of this debilitating neurological disease, given the current limitations in treatment options.
  • A targeted literature review was conducted to gain insights into the clinical, humanistic, and economic burden of mild-to-moderate AD, including mild cognitive impairment (MCI).

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
Friday, April 26, 2024
COVID-19, Public Policy, Other Policy Issues, Healthcare Reform, Pharmaceutical, Social Activism, Communications, General Health, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Foundation, AIDS, Health, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement.

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement.
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

Retrieved on: 
Wednesday, April 10, 2024
Komodo, Psoriatic arthritis, Arthropathy, Holocene, HS, Skin, Hidradenitis suppurativa, Partnership, Research, Literature, Entrepreneurship, Disease, Steroid, Patient, Inflammation, Marketing, Moonlake, Prevalence, Pharmaceutical industry

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams.
  • Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.
  • Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.

YC-Backed Yoneda Labs Raises $4 Million Seed Led by Khosla Ventures to Build Foundation Model for Chemists

Retrieved on: 
Friday, April 26, 2024
Science, Software, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Technology, University, Machine learning, Khosla Ventures, YC, Literature, Automation, Chemistry, Robotics, University of California, Berkeley, Y Combinator, Drug development, Drug discovery, Running, Algorithm, UC, Pharmaceutical industry

Yoneda Labs , the Y Combinator startup building a foundation model for chemists working in drug discovery, today announced it has raised $4 million in seed capital from Khosla Ventures, 500 Emerging Europe, 468 Capital, Fellows Fund, and Y Combinator.

Key Points: 
  • Yoneda Labs , the Y Combinator startup building a foundation model for chemists working in drug discovery, today announced it has raised $4 million in seed capital from Khosla Ventures, 500 Emerging Europe, 468 Capital, Fellows Fund, and Y Combinator.
  • “At Yoneda, our vision is to build a foundation AI model that analyzes and predicts what will happen before a chemist has to run their experiment.
  • Yoneda Labs was founded by a group from the University of Cambridge with backgrounds in chemistry, robotics, and machine learning.
  • During their time at YC, the team identified 20,000 chemical reactions to generate proprietary data for their foundation model.

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
Wednesday, April 24, 2024
COVID-19, Infectious Diseases, Public Policy, Government, AIDS, Health, Pharmaceutical, General Health, Other Policy Issues, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024 , Proposal for the WHO Pandemic Agreement.

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024 , Proposal for the WHO Pandemic Agreement.
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .